ArticleCureus2026
Immune Hyperactivation in Epstein-Barr Virus (EBV)-Driven T-cell Lymphoproliferation: A Pediatric Case of Hemophagocytic Syndrome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) triggered by Epstein-Barr virus (EBV)-associated T-cell lymphoproliferation represents a rare, aggressive complication in immunocompetent children, often mimicking lymphoma and leading to cytokine storm and multiorgan failure. This case report describes a six-year-old girl presenting with fever, cervical mass, hepatosplenomegaly, and cytopenias. Diagnostic evaluation included imaging (CT scans), serology, EBV polymerase chain reaction (PCR) (viral load 545,238 copies/mL), lymph node biopsy showing cytotoxic T-cell proliferation, and serial labs confirming HLH-2004 criteria (fever, splenomegaly, hypertriglyceridemia, cytopenias, hyperferritinemia >500 ng/mL, and hypofibrinogenemia). Treatment involved antibiotics, rituximab, chemotherapy, and HLH-2004 protocol (etoposide, corticosteroids, and cyclosporine). Initial antibiotic therapy addressed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.